RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1

被引：0
|
作者：
Manns, M. P. [1 ]
Poordad, F. [2 ]
Bacon, B. R. [3 ]
Bruno, S. [4 ]
Esteban, R. [5 ]
Silva, M. [6 ]
Buti, M. [7 ]
Burroughs, M. [7 ]
Sniukiene, V. [7 ]
Boparai, N. [7 ]
Brass, C. A. [7 ]
Albrecht, J. K. [7 ]
Bronowicki, J. -P. [8 ]
机构：
[1] Hannover Med Sch, D-3000 Hannover, Germany
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] St Louis Univ, Sch Med, St Louis, MO USA
[4] AO Fatebenefratelli & Oftalm, Milan, Italy
[5] Vall dHebron Univ Hosp, Barcelona, Spain
[6] Hosp Univ Austral, Pilar, Argentina
[7] Merck, Whitehouse Stn, NJ USA
[8] Univ Henri Poincare Nancy, Vandoeuvre Les Nancy, France
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)60450-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
448
引用
收藏
页码：S182 / S183
页数：2
相关论文
共 50 条
  • [1] Response-Guided Therapy With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin Reduces Treatment Duration in NaiVE and Peginterferon Alfa-2B/Ribavirin Previous-Treatment-Failure Patients With HCV Genotype 1
    Manns, Michael P.
    Poordad, Fred
    Bacon, Bruce R.
    Bruno, Savino
    Esteban, Rafael
    Silva, Marcelo O.
    Buti, Maria
    Burroughs, Margaret
    Sniukiene, Vilma
    Boparai, Navdeep
    Brass, Cliflord A.
    Albrecht, Janice K.
    Bronowicki, Jean-Pierre
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S942 - S942
  • [2] FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN
    Vierling, J. M.
    Lawitz, E. J.
    Poordad, F.
    Sulkowski, M. S.
    Bourliere, M.
    Buti, M.
    Cooper, C.
    Galati, J. S.
    Albrecht, J. K.
    Boparai, N.
    Brass, C. A.
    Burroughs, M.
    Sniukiene, V.
    Bruno, S.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S197 - S197
  • [3] Four-Week Therapy With Peginterferon Alfa-2B/Ribavirin Effectively Predicts Sustained Virologic Response in Treatment-NaiVE and Previous-Treatment-Failure Patients With HCV-1 Treated With Boceprevir Plus Peginterferon Alfa-28/Ribavirin
    Vierling, John M.
    Lawitz, Eric J.
    Poordad, Fred
    Sulkowski, Mark
    Bourliere, Marc
    Buti, Maria
    Cooper, Curtis
    Galati, Joseph
    Albrechi, Janice K.
    Boparai, Navdeep
    Brass, Clifford A.
    Burroughs, Margaret
    Sniukiene, Vilma
    Bruno, Savino
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S908 - S908
  • [4] SAFETY BENEFITS OF RESPONSE-GUIDED THERAPY WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR) IN PREVIOUSLY UNTREATED PATIENTS WITH HCV GENOTYPE 1 INFECTION
    Manns, Michael P.
    McCone, Jonathan
    Davis, Mitchell
    Shiffman, Mitchell L.
    Rossaro, Lorenzo
    Bourliere, Marc
    Pedicone, Lisa
    Burroughs, Margaret
    Brass, Clifford A.
    Albrecht, Janice K.
    Bruno, Savino
    [J]. HEPATOLOGY, 2011, 54 : 813A - 813A
  • [5] OVERALL SAFETY PROFILE OF BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN
    Manns, M. P.
    Felizarta, F.
    Schiff, E.
    Burroughs, M.
    Sniukiene, V.
    Boparai, N.
    Brass, C. A.
    Albrecht, J. K.
    Vierling, J. M.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S183 - S183
  • [6] Overall Safety Profile of Boceprevir Plus Peginterferon Alfa-2B/Ribavirin
    Manns, Michael P.
    Felizarta, Franco
    Schiff, Eugene R.
    Burroughs, Margaret
    Sniukiene, Vilma
    Boparai, Navdeep
    Brass, Clifford A.
    Albrecht, Janice K.
    Vierling, John M.
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S945 - S945
  • [7] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients
    Laguno, M
    Murillas, J
    Blanco, JL
    Martínez, E
    Miquel, R
    Sánchez-Tapias, JM
    Bargallo, X
    García-Criado, A
    de Lazzari, E
    Larrousse, M
    León, A
    Loncá, M
    Milinkovic, A
    Gatell, JM
    Mallolas, J
    [J]. AIDS, 2004, 18 (13) : F27 - F36
  • [8] Peginterferon alfa-2b plus ribavirin for chronic hepatitis
    Cecil, BD
    [J]. LANCET, 2002, 359 (9302): : 263 - 264
  • [9] Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin
    Brixner, Diana I.
    Ye, Xin
    Chu, Teng-Chiao
    Blumentals, William A.
    Hassanein, Tarek I.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (24) : 2171 - 2178
  • [10] A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection
    Suzuki, Fumitaka
    Toyota, Joji
    Ikeda, Kenji
    Chayama, Kazuaki
    Mochida, Satoshi
    Hayashi, Norio
    Ishikawa, Hiroki
    Miyagoshi, Hidetaka
    Hu, Wenhua
    McPhee, Fiona
    Hughes, Eric A.
    Kumada, Hiromitsu
    [J]. ANTIVIRAL THERAPY, 2014, 19 (05) : 491 - 499
12345